Evidence map›Paper›PMID 35893515›Full record

ReviewNanomaterials (Basel, Switzerland)2022

Progress in Antiviral Fullerene Research.

Piao-Yang Xu, Xiao-Qing Li, Wei-Guang Chen, Lin-Long Deng, Yuan-Zhi Tan, Qianyan Zhang, Su-Yuan Xie, Lan-Sun Zheng

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Effect of Fullerenol CNanomaterials (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Fullerenol CAntioxidants (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Article
  7. Highly aqueously stable CSmart medicine · 2023
    Article
  8. Nanomaterials and Their Impact on the Immune System.International journal of molecular sciences · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Piao-Yang XuCollege of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
Xiao-Qing LiFunano New Material Technology Company Ltd., Xiamen 361110, China.
Wei-Guang ChenFunano New Material Technology Company Ltd., Xiamen 361110, China.
Lin-Long DengPen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen 361005, China.ORCID 0000-0002-8588-1825
Yuan-Zhi TanCollege of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
Qianyan ZhangCollege of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.ORCID 0000-0002-4244-756X
Su-Yuan XieCollege of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
Lan-Sun ZhengCollege of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.

Funding

Funds of the Science and Technology Project of Yunnan Province-Major Project 202101AS070049National Natural Science Foundation of China 91961113, 21721001, 92061204, 21827801 and 92061000Xiamen Youth Innovation Fund 3502Z20206054
6 · The paper itself

Abstract

Unlike traditional small molecule drugs, fullerene is an all-carbon nanomolecule with a spherical cage structure. Fullerene exhibits high levels of antiviral activity, inhibiting virus replication in vitro and in vivo. In this review, we systematically summarize the latest research regarding the different types of fullerenes investigated in antiviral studies. We discuss the unique structural advantage of fullerenes, present diverse modification strategies based on the addition of various functional groups, assess the effect of structural differences on antiviral activity, and describe the possible antiviral mechanism. Finally, we discuss the prospective development of fullerenes as antiviral drugs.

Indexed as

antivirusfullerenenanodrugwater-soluble fullerene derivatives

Identifiers

PMID35893515
PMCPMC9330071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.